United States

Life sciences supply chain considerations during a pandemic


The pandemic has caused a renewed sense of urgency around supply chain repatriation or nearshoring discussions for U.S. life sciences companies. Along with geopolitical uncertainty related to tariffs as well as the U.S. election, the current environment may compel businesses to assess whether they need to shift aspects of their supply chains, and how to make those current supply chains more resilient.

In this recorded webcast from the recent virtual, Finance & Accounting for Bioscience Companies, RSM US LLP’s Jake Winquist, strategy and management consulting director, discusses the business continuity cycle around repatriating pieces of life sciences supply chains. Crucial aspects of this strategy include:

  • Developing a broad supply base that is resilient in the face of global disruption
  • Mitigating risk, security and privacy through the transition
  • Aligning the inventory strategy throughout the value chain
  • Understanding changing guidance and legislation developed to create incentives
  • Leveraging technology to remain compliant and gain efficiencies

Such changes do not happen overnight and can be overwhelming if companies are not well-prepared for them. It is important to have a plan for assessing and mitigating risk and potential supply shocks. Tune in to hear how RSM can help your business navigate this process.

Download webcast slides

Related Insights


Amid pressure to reshore life science supply chains, challenges abound

We suggest stress-testing your supply chain to determine what the actual or opportunity costs of disruption might be.

Supply Chain Services

Accelerate your organization's future with innovative supply chain and operations solutions from RSM’s experienced team.


Subscribe to Life Sciences newsletter